You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameGalantamineProduct NameRAZADYNE®Therapeutic AreaNervous SystemProduct ClassPsychoanalepticsPharmacological SubgroupAnti-Dementia DrugsChemical SubgroupAnticholinesterasesCondition StudiedAlzheimer Disease
Sponsor Protocol NumberGAL-INT-6Enrollment593Data PartnerJohnson & Johnson% Female48.0%Mean/Median Age (Years)75.0% White99.0%
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
- 2023-5295 : Individual-level and study-level predictors of neuropsychiatric symptom placebo response in Alzheimer's Disease clinical trials
- 2021-4836 : Adverse events of acetylcholinesterase inhibitors - systematic review and meta-analysis of double-blind randomized controlled trials
- 2016-0765 : Improving the statistical analysis of cognitive outcomes in randomised controlled trials: The 'Optimising the Analysis of Cognition' Collaboration